Antiangiogenic treatment, specific EGFR-targeting, and immune-checkpoint blockade could be a possible line of further improvement in existing treatments and investigational drugs, though it is important to note that the comparison and evaluation of results in glioma clinical research could be complicated due to very low therapeutic success and a low cohort of diagnosed GBM patients entering clinical trials (<5%) [299]. This evidence concerns the gene EGFR and glioma.